Individual.com logo
Welcome   (I'm not )
Select a date:

My Topics
Click here to add topics
Table bottom

My Companies
Click here to add companies
Table bottom

Newsdesks
Business
Finance
Internet
Computing
Environmental
Energy
Healthcare
Industry News, A-Z
Sports
Telecom
Transportation
Table bottom

Search
Google News
Table bottom

My Settings
Topics
Companies
Personal Info
Preferences
Forgot Password?
Log out
Table bottom

Top Topics
No top stories
Table bottom

Top Topics
Alternative Energy
Financial Services & Investing
Economic Indicators
Labor
Commodities & Futures
International and US Foreign Trade
Obesity, Weight Control & Nutrition
Aerospace & Defense
Crime & Law Enforcement
Hospital Industry
Table bottom

Pharmaceuticals & Drug Approval
Read the full report: https://www.reportlinker.com/p04368326 The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for...
PR Newswire, 10:08am ET



Nativis, Inc., a clinical-stage therapeutic device company developing non-sterile, non-invasive, non-thermal treatments for cancers and other serious diseases, announced it has received notice from the Food & Drug...
BusinessWire, 8:08am ET

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced receipt of tentative approval from the U.S. Food and Drug Administration (FDA) under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application...
PR Newswire, 7:38am ET

Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that the National Comprehensive Cancer Network (NCCN) has updated its medical guidelines for prostate cancer treatment to broadly include biomarker testing in prostate cancer. The changes to the...
GlobeNewswire, 7:13am ET

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, causes lethal respiratory paralysis within several years of diagnosis. There are no effective treatments to slow or halt this devastating disease. Mouse models of ALS...
PR Newswire, 1:23pm ET

Lumere, the leading provider of data-driven analytics, evidence and expert guidance to help health systems reduce unnecessary clinical variation and costs, today announced the appointment of Scott A. Falk, MD, to the firm's Physician Advisory...
GlobeNewswire, 12:08pm ET

Prime Therapeutics LLC (Prime), a leading pharmacy benefit manager (PBM) with more than 27 million members nationally, issued its annual 2017 drug trend results today, reporting its clients saw overall expenditure reductions (per member per...
PR Newswire, 11:03am ET

DURECT Corporation (Nasdaq: DRRX) today announced it will host a key opinion leader (KOL) call on the treatment of primary sclerosing cholangitis (PSC) on Monday, February 26 at 12:00 p.m. Eastern Time. The call will feature a...
PR Newswire, 8:08am ET

Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company") announced today that representatives from the Company's executive and clinical development teams will be attending the BMT Tandem Meetings, the combined annual...
GlobeNewswire, 7:38am ET

Merrimack Pharmaceuticals (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced the formation of a new Scientific Advisory Board (SAB), comprised of world-renowned experts in precision oncology,...
PR Newswire, 7:08am ET

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it has licensed IONIS-AZ5-2.5Rx (AZD2373) to the global, science-led biopharmaceutical company AstraZeneca (NYSE: AZN). IONIS-AZ5-2.5Rx is a Generation 2.5 antisense drug, discovered...
PR Newswire, 7:08am ET

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE: TFX) focused on addressing unmet needs in the field of urology, today announced that the U.S. Food and Drug Administration (FDA) has cleared new indications...
BusinessWire, 6:38am ET

Vical Incorporated (Nasdaq:VICL) announced today the initiation of a Phase 2 trial of the Company's VL-2397 novel antifungal compound. The multicenter, open label randomized clinical study, will compare the efficacy and safety of VL-2397 to...
GlobeNewswire, 6:08am ET

CytoDyn Inc. (OTC.QB:CYDY) reports the successful achievement of the primary endpoint in its CD02 Phase 2b/3 pivotal clinical trial with PRO 140 in combination with existing antiretroviral therapy (ART) in patients failing their current HIV...
GlobeNewswire, 6:08am ET

The Center for Information and Study on Clinical Research Participation (CISCRP), a Boston-based nonprofit organization, has released a new educational video called the "MT Pharmacy". Sponsored by Sanofi US, the digital public service...
PRWeb, 4:08am ET

STOCKHOLM, Feb. 20, 2018 /PRNewswire/ -- Business operations Significant events October-December 2017 Important events after the end of the period Financial information Fourth quarter (October-December...
PR Newswire Europe, 2:58am ET

Business operations Significant events October-December 2017 -- NeuroVive received a positive opinion from the EMA's Committee for Orphan Medicinal Products (COMP) regarding orphan drug designation for KL1333. -- Greg...
PR Newswire, 2:53am ET

MADRID, SPAIN and CAMBRIDGE, MA--(Marketwired - February 20, 2018) - Oryzon Genomics, S.A. (ISIN Code: ES0167733015) (MAD: ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong...
Marketwire Canada, 8:18am ET

MADRID, SPAIN and CAMBRIDGE, MA--(Marketwired - February 20, 2018) - Oryzon Genomics, S.A. (ISIN Code: ES0167733015) (MAD: ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong...
Marketwired, 8:13am ET

Scientists at Cedars-Sinai and Emulate, Inc. are pioneering a Patient-on-a-Chip program to help predict which disease treatments would be most effective based on a patient's genetic makeup and disease variant--a new...
BusinessWire, 8:08am ET

1-20 of 382
Next 20 >>


Tell a Friend About Us

Home Help My Settings Privacy Policy Terms of Service Advertising About Us Contact Us Logout

Copyright 1995-, Individual.com. No redistribution allowed.